Life Technologies

Life Technologies launches EZQC Online

Monday, September 30, 2013 02:46 PM

Life Technologies, a global biotechnology company, has launched EZQC Online, a web-based tool for quality control management in molecular diagnostic labs. EZQC Online contains three modules: a guidance tool for initial validation and verification of molecular tests, a tool to help labs meet CLIA standards for calibration verifications and a tool for ongoing quality control monitoring that provides an opportunity for peer-to-peer comparisons.

More... »

Thermo Fisher Scientific to acquire Life Technologies

Tuesday, April 16, 2013 11:29 AM

Thermo Fisher Scientific, a healthcare equipment company, has signed a definitive agreement to acquire Life Technologies, a global biotechnology tools company, for $76.00 in cash per fully diluted common share, or approximately $13.6 billion, plus the assumption of net debt at close ($2.2 billion as of year end 2012).

More... »

Life Technologies establishes international influenza network

Friday, February 1, 2013 01:14 PM

Life Technologies, a global biotechnology company, has established the Global Influenza Network, a partnership including scientists at a number of the world's leading government public health organizations, veterinary agencies and research institutes in a collaborative effort to increase the speed and efficiency of influenza monitoring and vaccine development.

More... »

Life Technologies acquires Compendia Bioscience

Tuesday, October 9, 2012 02:54 PM

Carlsbad, Calif.-based Life Technologies is acquiring Compendia Bioscience, a cancer bioinformatics company helping the pharmaceutical industry to identify novel gene targets for drug discovery and development.

More... »

CollabRx partners with Life Technologies in molecular diagnostics

Friday, October 5, 2012 08:00 AM

CollabRx, a provider of cloud-based expert systems to inform health care decision-making, has formed a multi-year partnership agreement with Life Technologies, global biotechnology tools company for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologies' global cancer diagnostics development and its laboratory developed test services business.

More... »

Knome introduces knoSYS100, first plug-and-play human genome interpretation system

Friday, September 28, 2012 12:10 PM

Knome, a Cambridge, Mass.-based provider of human genome interpretation systems and services, has launched its knoSYS100, the first plug-and-play, fully integrated hardware and software system designed to help researchers in medical and academic institutions interpret human whole genomes.

More... »

Life Technologies, BMS to partner on diagnostics development

Monday, September 17, 2012 01:17 PM

Life Technologies, a global biotech, has entered into a master development agreement with Bristol-Myers Squibb for current and future companion diagnostics projects.

More... »

Thirty teams compete to interpret three families' genomes

Monday, August 20, 2012 12:08 PM

In a contest led by Boston Children's Hospital, 30 teams from around the world are vying to interpret the DNA sequences of three children with rare conditions whose cause remains a mystery—with the goal of establishing "best practices" for interpreting genomic data.

More... »

New York Genome Center launches innovation center

Thursday, August 2, 2012 11:42 AM

New York Genome Center (NYGC), a non-profit engaged in a cooperative effort to transform medical research and clinical care, has launched its innovation center, which will provide access to new sequencing technologies and foster collaboration among NYGC’s institutional founding members (IFMs) and technology collaborators.

More... »

Life Technologies, GSK ink cancer research agreement

Wednesday, October 26, 2011 10:55 AM

Life Technologies has signed an agreement with GlaxoSmithKline to develop a diagnostic to be used as a companion test with a GSK candidate cancer immunotherapy. Life will develop a qPCR-based molecular diagnostic assay for GSK's MAGE-A3 cancer immunotherapy candidate designed to identify patients likely to benefit from the immunotherapy.

More... »